Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Prevention of Hepatic Encephalopathy
NCT00298038Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Dec 2005
- Primary completion
- Aug 2008
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of rifaximin in hepatic encephalopathy (HE), sponsored by Valeant Pharmaceuticals. Started Dec 2005; status: completed.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT00298038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00298038.